Literature DB >> 9135638

Prospective comparison of fast SE and GRASE sequences and echo planar imaging with conventional SE sequences in the detection of focal liver lesions at 1.0 T.

G Jung1, T Krahe, H Kugel, J Gieseke, U Hahn, C Walter, K Lackner.   

Abstract

PURPOSE: Our goal was to investigate the value of T2-weighted fast SE (FSE) sequences, FSE sequences with shortened echo spacing (UFSE), combined gradient and spin echo sequences (GRASE), and segmented T1-weighted echo planar imaging (EPI) in comparison with conventional SE sequences in the detection of focal liver lesions.
METHOD: Thirty-five patients with malignant focal liver lesions underwent MRI at 1.0 T.
RESULTS: All fast T2-weighted imaging techniques (FSE, UFSE, GRASE) showed fewer artifacts and overall better image quality than the conventional SE sequence. Quantitative analysis demonstrated that UFSE imaging had the highest tumor/liver contrast/noise ratio (C/N) (13.9 +/- 5.5) followed by FSE (12.7 +/- 4.5), T2 SE (10.9 +/- 4.2), and GRASE (10.0 +/- 4.8) sequences. The differences in C/N between the UFSE and T2 SE sequences was statistically significant (p < 0.05). C/N was significantly higher (p < 0.01) for the T1 SE (-7.4 +/- 3.8) than for the EPI sequence (-0.5 +/- 5.6).
CONCLUSION: FSE sequences with shortened echo spacing are valuable for liver imaging at 1.0 T. In comparison with the T2 SE sequence, they yielded better image quality and comparable tumor/liver C/N.

Entities:  

Mesh:

Year:  1997        PMID: 9135638     DOI: 10.1097/00004728-199705000-00002

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  1 in total

1.  Magnetic resonance cholangiopancreatography with GRASE sequence at 3.0T: does it improve image quality and acquisition time as compared with 3D TSE?

Authors:  Morikatsu Yoshida; Takeshi Nakaura; Taihei Inoue; Shota Tanoue; Sentaro Takada; Daisuke Utsunomiya; Shota Tsumagari; Kazunori Harada; Yasuyuki Yamashita
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.